Trial Profile
A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2019
Price :
$35
*
At a glance
- Drugs Udenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 12 Jun 2019 Primary endpoint has not been met. (Phase IIb - 6-minute walk distance), as reported in an article published in the Clinical Therapeutics
- 12 Jun 2019 Results published in the Clinical Therapeutics
- 17 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.